MCK stock forecast: what analysts expect
Wall Street analysts covering McKesson Corporation currently rate the stock a Buy on average, with a mean 12-month price target of $991.40 — +12.8% versus the last price of $878.73. Targets reflect analyst opinion, not a guarantee.
MCK historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in MCK.
MCK annual returns by year
Congress trading in MCK
18 members of Congress have disclosed trading MCK — 25 purchases and 11 sales worth an estimated $312,500. Most recent disclosure: Jul 8, 2026.
See who in Congress traded MCK →Insider activity in MCK
MCK's own executives and directors have made 0 open-market purchases ($0) and 10 sales ($23.9M) in the last 90 days, per SEC Form 4 filings. Most recent: Aug 10, 2026.
| Aug 10, 2026 | Lerman Bradley E | Director | Sell | $268,590 |
| Jul 7, 2026 | Tyler Brian S. | Chief Executive Officer | Sell | $6.7M |
| Jun 17, 2026 | Tyler Brian S. | Chief Executive Officer | Sell | $6.6M |
| Jun 9, 2026 | Tyler Brian S. | Chief Executive Officer | Sell | $3.8M |
| Jun 5, 2026 | Rutledge Napoleon B JR | SVP, Controller & CAO | Sell | $101,612 |
About McKesson Corporation
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
MCK Key Statistics
MCK in plain English
- P/E ratio (24.2) — how many dollars you pay for each $1 of MCK's yearly profit. That's a fairly normal range.
- Profit margin (1.12%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend yield (0.43%) — the cash payout you'd earn per year as a % of the share price, on top of any price gains.
MCK stock: frequently asked questions
What is McKesson Corporation's stock price today?
McKesson Corporation (MCK) last traded at $878.73 on the NYSE. Over the past 52 weeks the stock has traded between $661.69 and $999.00.
Is MCK stock a buy or a sell?
Wall Street analysts' consensus rating on MCK is "Buy", with an average 12-month price target of $991.40 — about +12.8% versus the current price of $878.73. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in MCK 10 years ago be worth today?
A $1,000 investment in McKesson Corporation made 10 years ago would be worth about $5,130 today (dividends reinvested) — a total return of 413%, or 17.8% per year.
Does MCK pay a dividend?
Yes. McKesson Corporation currently pays a dividend yielding about 0.43% per year at today's share price.
What is MCK's P/E ratio?
MCK trades at a trailing price-to-earnings ratio of 24.2, and 17.4 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade MCK stock?
Yes — 18 members of Congress have disclosed trades in MCK under the STOCK Act, totaling 25 purchases and 11 sales worth an estimated $312,500.
What is McKesson Corporation's ticker symbol?
McKesson Corporation trades under the ticker symbol MCK on the NYSE.
Compare MCK with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.